MTOR and cancer: The EGFR monoclonal antibody cetuximab combined with radiotherapy significantly improved overall survival at 5 years compared to radiotherapy alone in patients with locoregionally advanced head and neck cancer.74 The targeting of multiple targets within the EGFR/PI3K/Akt/mTOR pathway is currently under development, which may reduce radioresistance and further improve the clinical prognosis of cancer patients.126–130